Multi-center, double-blind, randomized, placebo-controlled, active reference, parallel-group, polysomnography dose response study to assess the efficacy and safety of ACT-541468 in adult subjects with insomnia disorder

Actelion Pharmaceuticals Ltd0 个研究点目标入组 300 人开始时间: 2016年8月26日最近更新: 2017年7月24日

试验速览

暂无简介。

•- Signed informed consent prior to any study-mandated procedure
•- Male or female aged 18-64 years (inclusive)
•- Women of childbearing potential must have a negative and urine pregnancy test and use reliable methods of contraception up to 30 days after EOT
•- Body mass index (BMI): 18.5 = BMI (kg/m2) < 32.0
•- Insomnia disorder according to DSM-5 criteria
•- Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by
•polysomnography.
•- Insomnia Severity Index score = 15.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.
•- Self-reported usual daytime napping = 1 hour per day, and = 3 days per week.
•- Caffeine consumption = 600 mg per day.
•- Shift work within 2 weeks prior to the screening visit, or planned shift work during study.
•- Travel = 3 time zones within 1 week prior to the screening visit, or planned travel = 3 time zones during study.
•- Hematology or biochemistry test results deviating from the normal range to a clinically relevant extent as per judgment of the Investigator.
•- AST and/or ALT > 2 × ULN and/or direct bilirubin > 1.5 × ULN
•- Severe renal impairment (known or defined as estimated creatinine clearance < 30 mL/min).
•- History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
•- Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

发起方